Canadian cost data associated with treating overactive bladder is lacking.

Autor: Viste D; University of Calgary, Calgary, AB, Canada., Barton C; University of Calgary, Calgary, AB, Canada., Carlson K; University of Calgary, Calgary, AB, Canada., Baverstock R; University of Calgary, Calgary, AB, Canada., Crump RT; University of Calgary, Calgary, AB, Canada.
Jazyk: angličtina
Zdroj: Canadian Urological Association journal = Journal de l'Association des urologues du Canada [Can Urol Assoc J] 2022 Mar; Vol. 16 (3), pp. E137-E145.
DOI: 10.5489/cuaj.7500
Abstrakt: Introduction: Cost-effectiveness analysis forms an integral part of the approval process for new medical treatments in Canada, including drug and non-drug technologies. This study's primary objective was to identify peer-reviewed studies that report Canadian-specific cost data for treating overactive bladder (OAB) based on the Canadian Urological Association (CUA) guideline. A secondary objective was to identify studies that report cost data from other healthcare jurisdictions that could be generalizable to the Canadian context.
Methods: We conducted a systematic review of the published peer-reviewed literature. We included studies from Organization for Economic Cooperation and Development countries, excluding the U.S., published in English since January 2009.
Results: From 165 abstracts identified in our initial search, 18 studies were ultimately included for analysis. This included one Canadian-based study reporting costs in Canadian dollars, all related to second-line treatments. The other studies were primarily from Europe, reporting costs in Euros or British pounds. There were no studies reporting costs for first-line treatments. Gaps in costs for select second-line and third-line treatments recommended by the CUA were also identified.
Conclusions: Canadian-specific cost data for OAB treatments published in the peer-reviewed literature is limited to a single study reporting costs for only a few second-line treatments sourced from a single province over 10 years ago. Cost data from other healthcare jurisdictions are available, but the generalizability of costs associated with third-line treatments is questionable.
Databáze: MEDLINE
Externí odkaz: